Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
P/B ratio for Ocean Biomedical, Inc. (OCEA)
P/B ratio as of 2022: 1.32
According to Ocean Biomedical, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.32. At the end of 2021 the company had a P/B ratio of -19.83.
P/B ratio history for Ocean Biomedical, Inc. from 2019 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | 1.32 |
| 2021 | -19.83 |
| 2020 | -106.86 |
| 2019 | -868.23 |